<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906280</url>
  </required_header>
  <id_info>
    <org_study_id>S58667</org_study_id>
    <nct_id>NCT02906280</nct_id>
  </id_info>
  <brief_title>RCT Comparing 19Ga vs 22Ga EBUS-TBNA Needles in Carcinoma.</brief_title>
  <official_title>Randomized Controlled Trial Comparing the Performance of 19 Gauge Versus 22 Gauge EBUS-TBNA Needles in Lung Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EBUS-TBNA is often the sole diagnostic test applied in patients with stage IV lung cancer. A
      limitation of the TBNA needle when using a 22 Gauge needle is the limited ability to procure
      adequate histological samples. Although a larger 19 Ga needle can procure histological
      samples as demonstrated by the conventional 19 Ga needle, published data are not existing
      with respect to molecular diagnostics. A new nitinol-based 19 Ga needle has been developed
      for EBUS-TBNA. Given the frequent usage of 22 Ga needles for molecular diagnostics and the
      recent technical advancements in 19 Ga needle technology, we conduct a RCT to compare the
      performance of both needle types.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with (suspected) stage IV lung carcinoma identified on spiral computed
      tomography scan and requiring an EBUS-TBNA investigation to obtain intrathoracic hilar or
      mediastinal lymph node tissue for diagnosis, subtyping and genotyping of lung cancer are
      eligible for participation in this study. Procedural technique : patients undergo an
      EBUS-TBNA procedure with either the Flex 19 Ga needle or the 22 Ga needle ; all procedures
      are performed using a linear array echoendosope under moderate sedation (standard practice).
      Primary endpoint of the study is the presence of core tissue that is defined as a continuous
      string of material as observed on the microscopic examination. Secondary endpoints are
      elements relevant to molecular analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue core</measure>
    <time_frame>14 months</time_frame>
    <description>Descriptive tissue characteristics of tumor sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor cellularity per area of diagnostic tissue</measure>
    <time_frame>14 months</time_frame>
    <description>Objective pathologic measurement of tumor density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of DNA extracted</measure>
    <time_frame>14 months</time_frame>
    <description>Objective measurement of the amount of DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of Next Generation Sequencing</measure>
    <time_frame>14 months</time_frame>
    <description>Feasibility of NGS testing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Lung Neoplasm</condition>
  <arm_group>
    <arm_group_label>19 Ga EBUS-TBNA needle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>needle aspiration by a flexible 19 Ga needle (Olympus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22 Ga EBUS-TBNA needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>needle aspiration by a 22 Ga needle (Olympus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EBUS-TBNA needle</intervention_name>
    <description>tissue sampling</description>
    <arm_group_label>19 Ga EBUS-TBNA needle</arm_group_label>
    <arm_group_label>22 Ga EBUS-TBNA needle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (suspected) stage IV lung carcinoma identified on spiral computed tomography scan

          -  requiring an EBUS-TBNA investigation to obtain intrathoracic hilar or mediastinal
             lymph node tissue for diagnosis

        Exclusion Criteria:

          -  uncontrolled coagulopathy

          -  tracheal stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe Dooms</last_name>
    <email>christophe.dooms@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals KU Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Decramer</last_name>
      <email>marc.decramer@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Christophe Dooms</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Christophe Dooms, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>EBUS-TBNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

